Neoadjuvant Treatment in Resectable Pancreatic Cancer
NCT01900327 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2018-05-11
Summary
Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma
Conditions
Interventions
- RADIATION
-
External Beam Radiation
Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
- DRUG
-
Gemcitabine neoadjuvant
weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
- PROCEDURE
-
Surgery
Upfront pancreato-duodenectomy
- DRUG
-
Gemcitabine adjuvant
Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
Sponsors & Collaborators
-
University Hospital Schleswig-Holstein
collaborator OTHER -
Hannover Medical School
collaborator OTHER -
St. Josef Hospital Bochum
collaborator OTHER -
University of Jena
collaborator OTHER -
SRH Wald-Klinikum Gera GmbH
collaborator OTHER -
Klinikum Darmstadt
collaborator OTHER -
Universität des Saarlandes
collaborator OTHER -
Heidelberg University
collaborator OTHER -
Staedtisches Klinikum Karlsruhe
collaborator OTHER -
University Hospital Freiburg
collaborator OTHER -
University Hospital Regensburg
collaborator OTHER -
Technical University of Munich
collaborator OTHER -
University Hospital Augsburg
collaborator OTHER -
Klinikum Stuttgart
collaborator OTHER -
Ludwig-Maximilians - University of Munich
collaborator OTHER -
University of Rostock
collaborator OTHER -
Universitätsklinikum Hamburg-Eppendorf
lead OTHER
Principal Investigators
-
Jakob R Izbicki, MD, FACS · Universitätsklinikum Hamburg-Eppendorf
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-02-28
- Primary Completion
- 2016-11-22
- Completion
- 2017-07-31
Countries
- Germany
Study Locations
More Related Trials
-
Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer
NCT01419002 ·Status: TERMINATED ·Phase: PHASE3
-
Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer
NCT01027221 ·Status: COMPLETED ·Phase: NA
-
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
NCT00335543 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01032057 ·Status: COMPLETED ·Phase: PHASE2
-
Preop Chemoradiation Resectable Pancreas
NCT00336648 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
NCT02318095 ·Status: COMPLETED ·Phase: NA
-
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
NCT06435260 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
NCT01314027 ·Status: TERMINATED ·Phase: PHASE3
-
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
NCT03572400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer
NCT01569282 ·Status: WITHDRAWN ·Phase: NA
-
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
NCT01531712 ·Status: TERMINATED ·Phase: PHASE2
-
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
NCT02723331 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study of Pancreatic Cancer
NCT00994721 ·Status: COMPLETED
-
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
NCT00010166 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
NCT00766636 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
NCT02349867 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
NCT04737551 ·Status: UNKNOWN
-
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01013649 ·Status: COMPLETED ·Phase: PHASE3
-
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
NCT05841420 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
NCT00038701 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Therapy in Biliary Adenocarcinoma
NCT04480190 ·Status: WITHDRAWN ·Phase: PHASE1
-
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
NCT00557492 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
NCT00425841 ·Status: COMPLETED ·Phase: PHASE2
-
Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01017822 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2